Cortexyme appoints Dr. Marwan Noel Sabbagh to Board as Class II director

Quince Therapeutics, Inc.

Dr. Sabbagh appointed Class II director effective March 14, 2022, term expires at 2024 annual meeting.
Entitled to $35,000 annual retainer under the company's Outside Director Compensation Policy.
Received initial equity grant of 22,058 nonstatutory stock options vesting in equal annual installments over three years.
Entered into standard form indemnification agreement with the company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Marwan Noel Sabbagh

Director

QNCX · Quince Therapeutics, Inc.

Effective: 2022-03-14
Filed: March 15, 2022, 7:59 PM ET

On March 14, 2022, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Cortexyme, Inc. (the “Company”), the Board appointed Marwan Noel Sabbagh, M.D., to serve as a Class II director of the Company, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Marwan Noel Sabbagh was appointed as Director at Quince Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 14, 2022, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Cortexyme, Inc. (the “Company”), the Board appointed Marwan Noel Sabbagh, M.D., to serve as a Class II director of the Company, effective immediately

View on SEC.gov

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-076267

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.